uniQure N.V. reported $19M of revenue over the trailing twelve months, +30% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $19M (to Q2 2026). Net income: −$252M, trailing twelve months to Q2 2026. Free cash flow: −$162M, trailing twelve months to Q2 2026. Operating margin: −1119%, trailing twelve months to Q2 2026.

QUREuniQure N.V.

Healthcare

$22.41-63% 1Y

$22.41

$9.0352 weeks$70.59

QURE as reported

uniQure N.V. reported $19M of revenue over the trailing twelve months, +30% on the year before. 10 reported series are charted on this page, each one as filed.

$19M

Revenue, trailing twelve months · to Q2 2026 · +30% against the twelve months before

Net income: −$252M
Net income · +27% year on year · trailing twelve months to Q2 2026
Free cash flow: −$162M
Free cash flow · −7.3% year on year · trailing twelve months to Q2 2026
Operating margin: −1119%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for QURE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$19M	+30%	Q2 2026
Net income	−$252M	+27%	Q2 2026
EPS	−$4.01	+2.3%	Q2 2026
Gross margin	92%	n/a	Q2 2026
Operating margin	−1119%	n/a	Q2 2026
Net margin	−1433%	n/a	Q2 2026
ROE	−105%	n/a	Q2 2026
ROA	−26%	n/a	Q2 2026
ROIC	37%	n/a	Q2 2026
Free cash flow	−$162M	−7.3%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.